{"id":"injections-of-tildrakizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tildrakizumab binds to the p19 subunit of IL-23, a key cytokine involved in the pathogenesis of psoriasis and other inflammatory skin conditions. By inhibiting IL-23 signaling, the drug suppresses the differentiation and activation of pathogenic T cells, particularly Th17 cells, thereby reducing skin inflammation and improving clinical outcomes in psoriatic disease.","oneSentence":"Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:10.966Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate to severe plaque psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT06611163","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2025-03-21","conditions":"Moderate to Severe Genital Psoriasis","enrollment":206},{"nctId":"NCT04314531","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":"Active Psoriatic Arthritis","enrollment":296},{"nctId":"NCT04991116","phase":"PHASE3","title":"Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2022-06-30","conditions":"Psoriatic Arthritis","enrollment":529},{"nctId":"NCT04314544","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":"Active Psoriatic Arthritis","enrollment":508},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT03552276","phase":"PHASE2, PHASE3","title":"Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2018-07-11","conditions":"Psoriatic Arthritis","enrollment":281},{"nctId":"NCT04971200","phase":"EARLY_PHASE1","title":"Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo","status":"COMPLETED","sponsor":"Premier Specialists, Australia","startDate":"2021-09-16","conditions":"Skin and Connective Tissue Diseases, Skin Diseases, Pigmentation Disorder","enrollment":12},{"nctId":"NCT05110313","phase":"PHASE4","title":"Effects of Tildrakizumab on Epigenetic Age","status":"COMPLETED","sponsor":"Carlos Wambier","startDate":"2022-04-08","conditions":"Psoriasis, Aging, Epigenetic Disorder","enrollment":30},{"nctId":"NCT05683015","phase":"PHASE4","title":"Therapeutic Drug Monitoring of Tildrakizumab in Psoriasis Patients","status":"UNKNOWN","sponsor":"University Hospital, Ghent","startDate":"2022-08-22","conditions":"Psoriasis Vulgaris","enrollment":100},{"nctId":"NCT04229836","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-12-17","conditions":"Plaque Psoriasis","enrollment":178},{"nctId":"NCT03718299","phase":"PHASE4","title":"A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2019-07-16","conditions":"Psoriasis","enrollment":55},{"nctId":"NCT02980692","phase":"PHASE2","title":"Efficacy and Safety Study of SUNPG1623","status":"COMPLETED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-04-19","conditions":"Active Psoriatic Arthritis","enrollment":391},{"nctId":"NCT04263610","phase":"PHASE4","title":"Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy","status":"COMPLETED","sponsor":"Almirall, S.A.","startDate":"2019-09-04","conditions":"Plaque Psoriasis","enrollment":190},{"nctId":"NCT01936688","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)","status":"WITHDRAWN","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2013-09","conditions":"Plaque-type Psoriasis","enrollment":""},{"nctId":"NCT02980705","phase":"PHASE2","title":"Efficacy and Safety Study of SUNPG1622","status":"TERMINATED","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2017-11-06","conditions":"Active Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis","enrollment":180},{"nctId":"NCT04347473","phase":"PHASE4","title":"ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.","status":"RECRUITING","sponsor":"Psoriasis Treatment Center of Central New Jersey","startDate":"2020-04-06","conditions":"Psoriasis","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":26,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Injections of tildrakizumab","genericName":"Injections of tildrakizumab","companyName":"Sun Pharmaceutical Industries Limited","companyId":"sun-pharmaceutical-industries-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses. Used for Moderate to severe plaque psoriasis, Psoriatic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}